Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial

•The first randomized trial of hydroxychloroquine in patients with a recent myocardial infarction.•Hydroxychloroquine reduced IL-6 levels more than placebo when treatment was continued six months.•Treatment with hydroxychloroquine was safe.•The number of adverse events did not differ between the hydroxychloroquine and placebo groups.•A larger trial is warranted to prove if hydroxychloroquine can reduce cardiovascular endpoints.